Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2026 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
In my latest article I wrote about the three newest drugs we have been blessed with: Intelence, Isentress, and Selzentry. All were approved by the Food and Drug Administration based on 24-week data from clinical trials, which means that enough patients had their viralload reduced to less than 50 after six months that the FDA was willing to approve the drug while more long-term results were collected. So it was reassuring to hear at this year's Conference on Retroviruses and Opportunistic Infections that the 48-week data confirmed their effectiveness. Selzentry and Isentress were approved in the second half of 2007, and each was the first drug in a totally new class of antiretrovirals. Intelence, approved in January, is a nonnucleoside reverse transcriptase inhibitor, like Sustiva and Viramune, but because it has resistance mutations different from the other nonnukes, it has the potential to have an impact on treatment options that are nearly the same as having another new drug class available. With Sustiva and Viramune, one single mutation at location K103N causes complete loss of anti-HIV activity by both drugs. Needless to say, K103N is now a common mutation. Intelence, on the other hand, is not affected by K103N. In fact, of the 12 nonnuke-resistant mutations defined by the International AIDS Society, it takes three or more mutations to reduce the effectiveness of this drug. In essence, it can resurrect the nonnucleoside class. As with Selzentry and Isentress, Intelence was approved based on a trial of three-class-resistant patients who were given an optimized salvage regimen with either Intelence or a placebo. At 48 weeks 61% of the patients on Intelence had undetectable viral loads compared to 40% who were given a placebo. Interestingly, in patients whose salvage regimen contained no other active drug, Intelence by itself got 45% of them to undetectability. Intelence is dosed as two tablets to be taken twice a day with food. A rash occurred in 17% of patients, mostly between weeks two and four, but only 2% of patients stopped the drug due to the rash. Nausea occurred in 14% of patients versus 11% of patients who were on a placebo (remember these were multidrug salvage regimens that they were being given). The one issue with this drug is its somewhat complicated metabolism pathways, which limit its combining options. While Intelence can be combined with any nucleoside reverse transcriptase inhibitor, the only protease inhibitors that it can be used with are Invirase or Prezista (each boosted) or with Kaletra. And it cannot be combined with any of the other nonnucleosides. Despite theses restrictions, we can extend a warm welcome to this newest kid on the block.
From our Sponsors
Most Popular
The road to U=U: How science has been liberating HIV+ people for a decade
July 01 2026 12:05 PM
Newly diagnosed with HIV? Advocates share their best advice for seeking treatment
April 29 2026 3:32 PM
How to find an HIV-competent healthcare provider, according to advocates
May 19 2026 4:55 PM
Plus: Featured Video
Latest Stories
A New Once-Daily Pill to Treat HIV Just Got the FDA’s Green Light
August 31 2026 2:31 PM
Why affirming faith communities belong in the fight to end HIV
August 30 2026 8:00 AM
Navigating a new HIV diagnosis? Advocates say community is key
August 25 2026 3:33 PM
Gay Wine Weekend toasts 15 years of raising funds for HIV
August 25 2026 11:00 AM
A new HIV diagnosis doesn't have to be nerve-wracking. Advocates share their advice
July 30 2026 12:01 PM
Zero HIV Stigma Day: The epidemic we still choose to ignore
July 21 2026 7:00 AM
National HIV Prevention Day: Awareness is my superpower
July 17 2026 8:00 AM
Federal court clarifies that people with HIV can join the military again
June 03 2026 5:36 PM
Can a single infusion of immune cells suppress HIV for years?
May 11 2026 11:39 AM
National HIV advocacy group's CEO rejects claims of crisis
April 21 2026 5:14 PM
Beyond awareness: How youth leadership is reshaping the HIV response
April 10 2026 9:12 AM
Saving public health? AIDS United's new CEO has a plan
March 23 2026 9:48 AM
Struggling with daily HIV meds? Monthly shots may be the answer
March 20 2026 7:12 AM
Trending stories
Recommended Stories for You

































































